Quick Answer
Cardlytics, Inc. reported R&D Expense of $39.77 million for fiscal year 2025.
Cardlytics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $39.77M | -19.8% |
| 2024 | $49.61M | -3.4% |
| 2023 | $51.35M | -5.7% |
| 2022 | $54.44M | +42.9% |
| 2021 | $38.10M | +117.3% |
| 2020 | $17.53M | +49.9% |
| 2019 | $11.70M | -27.8% |
| 2018 | $16.21M | +33.4% |
| 2017 | $12.15M | -12.6% |
| 2016 | $13.90M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.80M | -33.3% | -22.1% |
| June 30, 2025 | $11.29M | -16.1% | -3.5% |
| March 31, 2025 | $11.71M | -10.3% | -11.3% |
| September 30, 2024 | $13.19M | +6.1% | -2.0% |
| June 30, 2024 | $13.47M | -9.3% | +3.2% |
| March 31, 2024 | $13.05M | +12.8% | +5.0% |
| September 30, 2023 | $12.43M | -9.7% | -16.3% |
| June 30, 2023 | $14.85M | +9.3% | +28.4% |
- Cardlytics, Inc. showed a decrease of -19.8% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, Cardlytics, Inc.’s r&d expense has grown by 186.0% (from $13.90 million to $39.77 million).
- The most recent figure is from Cardlytics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: